Gustave Roussy Leads Europe's Cancer Care Overhaul with GrayOS AI

VILLEJUIF, FRANCE – May 19, 2026 – In a landmark move for European oncology, Gustave Roussy, the continent's leading cancer center, has announced the deployment of GrayOS, a sophisticated care orchestration platform. This makes the prestigious French institution the first in Europe to adopt the technology from developer Gray Oncology Solutions to streamline its complex radiation therapy operations, signaling a major step toward a more efficient and patient-centric future for cancer treatment.

The implementation targets Gustave Roussy's bustling radiation therapy department, which managed over 4,200 patients and 50,000 treatment sessions in 2025 with a team of 150 professionals. By integrating with the hospital's existing MOSAIQ and DxCare systems, the AI-driven platform will automate and optimize appointment scheduling, aiming to shorten patient wait times, maximize the use of high-tech treatment machines, and free clinical staff from hours of manual coordination.

A Strategic Leap Towards the 'Smart Hospital'

This technological upgrade is not an isolated initiative but a cornerstone of Gustave Roussy's ambitious 2030 Institutional Strategic Plan. Launched in 2020, the plan outlines a vision for achieving "ultra-individualisation" in cancer care through precision medicine and transforming the institution into a "smart hospital HQ for European oncology." The deployment of GrayOS directly addresses the plan's core objectives: modernizing patient pathways, improving multidisciplinary coordination, and equipping the center to handle ever-increasing patient volumes and treatment complexity.

As cancer therapies become more personalized and effective, they also become more logistically demanding. The existing software tools used by many hospitals were not designed for this new era of complex, multi-step patient journeys. The strategic plan acknowledges the urgent need for digital transformation and the integration of AI to optimize these intricate workflows.

Professor Éric Deutsch, Head of the Radiotherapy Department at Gustave Roussy, highlighted the necessity of this evolution. "Radiation therapy becomes more precise, more individualized, and more integrated with other therapeutic modalities every year," he stated. "This evolution, which directly benefits patients, also generates operational complexity that existing tools no longer absorb adequately. By deploying GrayOS, we are choosing an infrastructure capable of evolving at the pace of our discipline and our volumes, and one that allows our teams to focus on what matters most: the quality of care delivered to each patient."

Unlocking Efficiency in a Growing Market

The adoption of such technology reflects a broader trend across European healthcare. The market for oncology information systems (OIS) was valued at approximately $1.0 billion in 2025 and is projected to more than double to $2.2 billion by 2035. This growth is fueled by a rising cancer burden and a continental push toward digitization and precision medicine. Hospitals are increasingly seeking integrated solutions to manage the data deluge and operational challenges of modern oncology.

Gray Oncology Solutions enters this competitive European market, which includes giants like Siemens Healthineers and Oracle Health, with a significant endorsement. The partnership with Gustave Roussy serves as a powerful case study. However, the path is not without challenges. Technical integration remains a major hurdle in healthcare, with hospitals often running a patchwork of legacy systems. Achieving true interoperability—ensuring different software systems can seamlessly exchange data—is critical. GrayOS is designed as a vendor-agnostic "interoperability layer," a key feature for navigating Europe's fragmented IT landscape and strict data privacy laws like GDPR.

The Proven Impact on Patients and Providers

While the technology is new to Europe, its impact has been documented at institutions across North America. Case studies from other cancer centers deploying GrayOS validate the ambitious claims of increased efficiency. The Jewish General Hospital in Montreal reported a 13% gain in efficiency, allowing it to treat more patients with the same resources, coupled with an 80% reduction in the administrative burden of scheduling. Similarly, the Centre Hospitalier de l'Université de Montréal (CHUM) cut its scheduling time by 80% and unlocked additional treatment capacity.

These statistics translate into profound real-world benefits. For patients, it means potentially shorter wait times for critical treatment to begin, less uncertainty, and a smoother, more coordinated care journey. For healthcare providers, it means reclaiming valuable time. An 80% reduction in time spent on manual coordination allows nurses, therapists, and administrative staff to redirect their focus to direct patient interaction and care, reducing burnout and improving job satisfaction.

The Weight of Expert Endorsement

The significance of this deployment is amplified by the profile of its lead advocate, Professor Éric Deutsch. His role extends far beyond heading a hospital department. As a Full Professor at Paris-Saclay University and Director of a major INSERM research unit, he is a leading figure in the global effort to integrate technology and biology to advance cancer treatment. His research is dedicated to personalizing radiotherapy through AI, radiomics, and immunotherapy, and he leads a multi-million euro project on AI-guided radio-immunotherapy.

With over 300 scientific publications and a reputation for championing innovation, Professor Deutsch’s endorsement is more than a simple quote in a press release; it is a powerful validation from a key opinion leader at the intersection of clinical practice and cutting-edge research. His support signals to the wider European oncology community that care orchestration technology is not just a tool for administrative efficiency but a critical component of next-generation cancer care delivery. This partnership between a leading clinical innovator and a technology pioneer sets a new benchmark for how European hospitals can harness digital tools to meet the profound challenges of modern oncology.